ERBB2 and neoplasm: In treating parental tumor cells, we found that treatment of the Her2-overexpressing (Figure 3b) but Herceptin-resistant tumor cell line HR20 with a high concentration of EDC-Herceptin conjugate suppressed tumor cell viability, whereas treatment with wild-type Herceptin at the same concentration failed to affect HR20 cell growth (Figure 3a).